A61K 40/4237
Hormones
Official title: {Hormones, e.g. calcitonin}
A61K40/4237 (Hormones) appears on 7 US grants and 21 published applications in this corpus.
Search patents in A61K- Granted patents
- 7
- Published applications
- 21
- Assignees
- 20
- Inventors
- 55
- Latest grant
- 19 Mar 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 1 |
| 2003 | 0 | 0 |
| 2004 | 0 | 1 |
| 2005 | 0 | 1 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 1 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 1 | 0 |
| 2017 | 0 | 1 |
| 2018 | 1 | 1 |
| 2019 | 0 | 1 |
| 2020 | 1 | 2 |
| 2021 | 0 | 1 |
| 2022 | 0 | 3 |
| 2023 | 1 | 2 |
| 2024 | 2 | 2 |
| 2025 | 0 | 4 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Anti-mesothelin chimeric antigen receptor (CAR) constructs and uses thereof19 Mar 2024US 11,932,698 B2Nanjing Legend Biotech Co., Ltd.
- Use of chimeric antigen receptor modified cells to treat cancer19 Mar 2024US 11,932,700 B2Innovative Cellular Therapeutics Holdings, Ltd.
- Nipah virus envelope glycoprotein pseudotyped lentivirus21 Mar 2023US 11,608,509 B2Centre National de la Recherche Scientifique (CNRS)
- Use of chimeric antigen receptor modified cells to treat cancer6 Oct 2020US 10,793,638 B2Innovative Cellular Therapeutics, Inc.
- Use of chimeric antigen receptor modified cells to treat cancer3 Apr 2018US 9,932,405 B2Innovative Cellular Therapeutics, Inc.
- Methods and compositions to modulate t cell metabolism, function, and fate14 May 2026US 2026/0132175 A1Cornell University
- Cell therapies for type 1 diabetes25 Sep 2025US 2025/0295772 A1Abata Therapeutics, Inc.
- Icam-1 targeted car constructs and methods of treatment18 Sep 2025US 2025/0288611 A1
- Car constructs and methods of treatment4 Sep 2025US 2025/0276018 A1
- Foxp1-ablated chimeric cells5 Jun 2025US 2025/0179184 A1H. Lee Moffitt Cancer Center and Research Institute, Inc.
Most cited
By later US patents
- Use of chimeric antigen receptor modified cells to treat cancer13US 9,932,405 B2Innovative Cellular Therapeutics, Inc. · 2018
- Nipah virus envelope glycoprotein pseudotyped lentivirus7US 11,608,509 B2Centre National de la Recherche Scientifique (CNRS) · 2023
- Use of chimeric antigen receptor modified cells to treat cancer1US 10,793,638 B2Innovative Cellular Therapeutics, Inc. · 2020